LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

Home・Elenco Azioni・ADMA Biologics Inc

ADMA Biologics Inc

Aperta

SettoreSettore sanitario

7.73 2.38

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

7.45

Massimo

7.75

Metriche Chiave
By Trading Economics
Entrata	-4.1M 45M
Vendite	-25M 114M
P/E Media del settore	11.735 49.888
EPS	0.17
Margine di Profitto	39.59
Dipendenti	640
EBITDA	-13M 52M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+198.29% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-546M 1.8B
Apertura precedente	5.35
Chiusura precedente	7.73

Notizie sul Sentiment di mercato

By Acuity

79%

21%

301 / 344 Classifica in Healthcare

ADMA Biologics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 giu 2026, 20:30 UTC

Utili

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 giu 2026, 23:58 UTC

Discorsi di Mercato

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 giu 2026, 23:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 giu 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 giu 2026, 23:41 UTC

Discorsi di Mercato

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 giu 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 giu 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 giu 2026, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 giu 2026, 22:57 UTC

Discorsi di Mercato

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 giu 2026, 22:50 UTC

Discorsi di Mercato

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 giu 2026, 21:07 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 giu 2026, 21:07 UTC

Discorsi di Mercato

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 giu 2026, 21:00 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

2 giu 2026, 20:46 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:38 UTC

Utili

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 giu 2026, 20:21 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:12 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Product Rev $594M

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Loss $177M >PANW

Confronto tra pari

Modifica del prezzo

ADMA Biologics Inc Previsione

Obiettivo di Prezzo

By TipRanks

198.29% in crescita

Previsioni per 12 mesi

Media 22.67 USD 198.29%

Alto 30 USD

Basso 18 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ADMA Biologics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 3 che hanno fornito valutazioni azionarie a ADMA Biologics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

301 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.